Skip to main content
      Addressing Lupus Nephritis Timely
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All

      Dr. John Cush RheumNow

      4 months 1 week ago
      RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
      CAR-T: The Future
      Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO

      @Janetbirdope pearls in rheumatology.

      Sero negative infl

      Nouf Al hemmadi NoufAhmedAlham2

      4 months 1 week ago
      Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO @Janetbirdope pearls in rheumatology. Sero negative inflammatory arthritis ? Or is it? Look at the toes for early signs of PsA. In my clinic ITS inflammatory arthritis to determine etiology . @RheumNow #ACR25
      Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj

      @synovialjoints Elaborate more on head to head trial in

      Nouf Al hemmadi NoufAhmedAlham2

      4 months 1 week ago
      Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj @synovialjoints Elaborate more on head to head trial in PsA , in a population who failed TNF biologic. @RheumNow #ACR25
      What's the latest in PsA? https://t.co/I8ZgRQpVy6

      Great review for whats new in PsA by @drpnash

      Looking forward for

      Nouf Al hemmadi NoufAhmedAlham2

      4 months 1 week ago
      What's the latest in PsA? https://t.co/I8ZgRQpVy6 Great review for whats new in PsA by @drpnash Looking forward for Large IL23-Axial study results. @RheumNow #ACR25
      Day 3 Recap- ACR Convergence 2025 Highlights https://t.co/4ZiTWVVwhl

      The analogy used by @RheumNow to explain differe

      Nouf Al hemmadi NoufAhmedAlham2

      4 months 1 week ago
      Day 3 Recap- ACR Convergence 2025 Highlights https://t.co/4ZiTWVVwhl The analogy used by @RheumNow to explain difference between completion versus intention to treat analysis hahahaha. You look good either ways! @bella_mehta @RHEUMarampa @EBRheum
      #ACR25 Abstr#LB15 Tell #RA patients on methotrexate that eating high fibre diet is good for them! An RCT showed improved

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Abstr#LB15 Tell #RA patients on methotrexate that eating high fibre diet is good for them! An RCT showed improved EULAR response vs PBO. Likely due to restoration of Th17/Treg balance @RheumNow https://t.co/NbwQFqJNho
      #ACR25 Abstr#LB14 Promising therapyBMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago

      #ACR25 Abstr#LB14 Promising therapy BMS-986353, a CD19 CAR-T in Severe Refractory Idiopathic Inflammatory Myopathies. 11/12 had evaluable data; muscle, skin and ILD improved. 1 x G2 CRS, 1 G3 ICANS. Longer FU needed and larger sample @RheumNow https://t.co/zAG23tAsbL

      #ACR25 Abstr#2411 How good is performance of 2019 ACR-EULAR #SLE criteria at the point of diagnosis in At-Risk ANA+ peop

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 months 1 week ago
      #ACR25 Abstr#2411 How good is performance of 2019 ACR-EULAR #SLE criteria at the point of diagnosis in At-Risk ANA+ people? Our group compared this with Clinician dx -> high specificity(93.8%); low sensitivity(79.3%). Might be a cause why SMILE HCQ RCT failed in At-Risk @RheumNow https://t.co/6GNU2B2wvj
      Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts

      JAKi use: ⬆️incidence of HZ infxn but not sig

      sheila RHEUMarampa

      4 months 1 week ago
      Cohort study comparing 3yr safety outcomes of JAKi vs. TNFi in AS pts JAKi use: ⬆️incidence of HZ infxn but not significant; ⬆️all-cause mortality (HR 4.94) and GI bleed (p=0.04) Individualize tx. consider potential complications #ACR25 @RheumNow Abs2633 https://t.co/pjKAazQFwW
      Sex differences in 💊 d/c in axSpA from the RISE registry

      🔅Females - ⬆️discontinuation risks for TNFi
      🔅No

      sheila RHEUMarampa

      4 months 1 week ago
      Sex differences in 💊 d/c in axSpA from the RISE registry 🔅Females - ⬆️discontinuation risks for TNFi 🔅No sex differences seen in dc risks for IL17i and JAKis 🔅Young females discontinued faster than males Gender diff in SpA can guide tx decisions #ACR25 @RheumNow Abs2634 https://t.co/kcXfZrU4zI
      What a conference! Thanks to all those who stopped by! #ACR25 https://t.co/UMAqnPdK4t

      Dr. John Cush RheumNow

      4 months 1 week ago
      What a conference! Thanks to all those who stopped by! #ACR25 https://t.co/UMAqnPdK4t
      ×